December 1, 2021
Life Sciences
  • An advisory panel to the FDA narrowly endorsed Merck & Co. and Ridgeback Biotherapeutics LP’s COVID-19 antiviral pill for patients at high risk of severe illness. The treatment could be available to patients within weeks if the agency authorizes it. In the coming weeks, the FDA may also authorize a similar pill from Pfizer that appears to be significantly more effective than Merck’s. (Articles here, here, here, and here)